Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Promising MOD-5014 results in a phase I/IIa clinical trial in hemophilia patients

Feb. 3, 2017

Sustained factor IX activity seen with single infusion of SPK-9001 gene therapy

Feb. 3, 2017

Increased potency of CB-2679d may allow subcutaneous dosing for hemophilia B

Feb. 3, 2017

Biogen completes separation of global hemophilia business and launches Bioverativ

Feb. 3, 2017

EMA grants BioMarin's BMN-270 for hemophilia A access to PRIME initiative

Feb. 2, 2017

Dimension Therapeutics reports topline results from phase I/II program of lead AAV candidate

Feb. 1, 2017

FDA grants breakthrough therapy designation to uniQure's AMT-060 for hemophilia B

Jan. 31, 2017

Roxadustat meets primary endpoints in two phase III anemia trials in China

Jan. 31, 2017

Exemplar Genetics contracted to create models of sickle cell disease

Jan. 27, 2017

Bayer Pharma describes coagulation factor XIa and kallikrein B inhibitors

Jan. 24, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 9, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...